Jamalpoor A, van Gelder CA, Yousef Yengej FA, Zaal EA, Berlingerio SP, Veys KR, Pou Casellas C, Voskuil K, Essa K, Ammerlaan CM, Rega LR, van der Welle RE, Lilien MR, Rookmaaker MB, Clevers H, Klumperman J, Levtchenko E, Berkers CR, Verhaar MC, Altelaar M, Masereeuw R, Janssen MJ (2021) Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis
doi: 10.3390/molecules27010324
This specific biochemical modification creates a highly stable, lipophilic (fat-soluble) shield around the molecule
The GHIGF-1 axis helps mobilize fatty acids from adipose tissue and increases metabolic rate
Most therapeutic protocols use 12-24 week cycles based on research protocols and individual goals